10 Best Prefered Stocks To Watch Right Now

Wall Street is a very fickle mistress. Analysts that work on Wall Street often cannot see the forest for the trees. They are more concerned about defending their reputation than actually doing the heavy lifting that can really help an investor find top stocks to buy before they make their move.

UBS regularly puts out a research report on overwriting options on specific stocks. The most recent edition did not hold any great surprises, as the analysts are reluctant to be too aggressive with the volatility index (VIX) running low, but were inline with the average for the year. However they did point out some names that specifically they suggested not to overwrite. They also made some interesting comments on laggards that had turned into momentum stocks.

Momentum stocks are typically the ones people buy strictly on the notion that, even if they buy high, shares will go higher. This works great in a bull market like we are in, not so great if the market turns down. Here is an interesting list of names from UBS that were lagging the field and turned hot.

Top 10 Dividend Companies To Invest In Right Now: Abercrombie & Fitch Company(ANF)

Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer of casual apparel for men, women, and kids. The company sells casual sportswear apparel, including knit and woven shirts, graphic t-shirts, fleece, jeans and woven pants, shorts, sweaters, and outerwear; personal care products; and accessories under the Abercrombie & Fitch, abercrombie kids, and Hollister brands. It also offers bras, underwear, sleepwear, and at-home products for girls under the Gilly Hicks brand. The company sells products through its stores; direct-to-consumer operations; and Websites, which comprise abercrombie.com, abercrombiekids.com, hollisterco.com, and gillyhicks.com. As of October 29, 2011, it operated a total of 1,092 stores, including 316 Abercrombie & Fitch stores, 179 abercrombie kids stores, 501 Hollister Co. stores, and 18 Gilly Hicks stores in the United States; and 10 Abercrombie & Fitch stores, 4 abercrombie kids stores, 63 Hollister Co. stores, and 1 Gill y Hicks store internationally. The company was founded in 1892 and is headquartered in New Albany, Ohio.

Advisors' Opinion:

• [By Eddie Staley]

  Abercrombie & Fitch Co (NYSE: ANF) shot up 9.52 percent to $36.37 after the company lifted its adjusted earnings guidance for the year.

  Francesca's Holdings (NASDAQ: FRAN) was also up, gaining 21.74 percent to $22.01 after the company narrowed its Q4 revenue forecast to $93 million to $95 million from $90 million to $95 million. It projects earnings of $0.27 to $0.29 per share, versus its earlier forecast of $0.25 to $0.29 per share.

• [By Victor Reklaitis and Barbara Kollmeyer]

  Shares of Abercrombie & Fitch (ANF) fell 7% after the retailer late Tuesdasy said same-store sales sank 14%.

• [By Jim Jubak]

  But last Thursday, Target (TGT) and Abercrombie & Fitch (ANF) also reported disappointing third quarter sales.

  Which certainly suggests that the better-than-expected retail sales growth for October, reported by the Census Bureau earlier last week, is going to turn out��t best��o be very spotty indeed. At 0.4% growth in October, this isn't a tide running strong enough to lift all boats.

10 Best Prefered Stocks To Watch Right Now: Kilroy Realty Corp (KRC)

Kilroy Realty Corporation, incorporated on September 13, 1996, is a self-administered real estate investment trust (REIT). The Company focuses on office and industrial submarkets along the West Coast. The Company owns, develops, acquires and manages real estate assets, consisting primarily of Class A real estate properties in the coastal regions of Los Angeles, Orange County, San Diego County, the San Francisco Bay Area and greater Seattle. As of December 31, 2011, the Company�� portfolio consisted of 104 office buildings (the Office Properties) and 39 industrial buildings (the Industrial Properties). The Company owns its interests in all of its Office Properties and Industrial Properties through the Kilroy Realty, L.P. (the Operating Partnership) and Kilroy Realty Finance Partnership, L.P. (the Finance Partnership). In March 2012, the Company purchased Menlo Corporate Center in Menlo Park, California. In June 2012, the Company purchased two office properties in the Lake Union submarket of Seattle. In January 2013, the Company purchsed Westlake Terry, a two building 320,399 square-foot office property. In September 2013, the Company announced it has completed the purchase of a 13.8 acre Class A office campus in the coastal Del Mar sub-market of San Diego. Effective September 19, 2013, Kilroy Realty Corp acquired The Heights, a owner and operator of an office campus. In January 2014, Kilroy Realty Corp completed the disposition of 13 San Diego office properties in two tranches. In January 2014, Kilroy Realty Corp acquired from The Academy of Motion Pictures Arts and Sciences an approximate four-acre parcel near the intersection of Sunset Boulevard and Vine Street in Hollywood.

On January 28, 2011, the Company acquired one building in 250 Brannan Street, San Francisco, CA. On April 21, 2011, the Company acquired four buildings in 10210, 10220 and 10230 NE Points Drive; 3933 Lake Washington Boulevard NE, Kirkland, WA. On May 12, 2011, the Company acquired one building in 10770 Water! idge Circle, San Diego, CA. On June 3, 2011, the Company acquired one building in 601 108th Avenue N.E., Bellevue, WA. On June 9, 2011, the Company acquired one building in 4040 Civic Center Drive, San Rafael, CA. On September 15, 2011, the Company acquired one building in 201 Third Street, San Francisco, CA. On November 15, 2011, the Company acquired one building in 301 Brannan Street, San Francisco, CA. On December 15, 2011, the Company acquired one building in 370 Third Street, San Francisco, CA. In December 2011, it commenced redevelopment at one of its acquired properties in San Francisco. On January 30, 2012, the Company sold 15004 Innovation Drive, San Diego, CA and 10243 Genetic Center Drive, San Diego, CA. In September 2011, the Company disposed of its interest in 10350 Barnes Canyon and 10120 Pacific Heights Drive, San Diego, CA. In December 2011, the Company disposed of interest in 2031 E. Mariposa Avenue, Los Angeles, CA.

The Company conducts substantially all of its operations through the Operating Partnership of which as of December 31, 2011, it owned a 97.2% general partnership interest. Kilroy Realty Finance, Inc., a wholly owned subsidiary of the Company, is the sole general partner of the Finance Partnership. The Company conducts substantially all of its development activities through Kilroy Services, LLC (KSLLC), which is a wholly owned subsidiary of the Operating Partnership. Its wholly owned subsidiaries include Kilroy Realty TRS, Inc., Kilroy Realty Management, L.P., Kilroy RB, LLC, Kilroy RB II, LLC, Kilroy Realty Northside Drive, LLC and Kilroy Realty 303, LLC. As of December 31, 2011, the Company�� tenants included Intuit, Inc., Bridgepoint Education, Inc., Delta Dental of California, AMN Healthcare, Inc., Hewlett-Packard Company, Fish & Richardson P.C., Scripps Health and Epson America, Inc.

Advisors' Opinion:

• [By Rich Duprey]

  Real estate investment trust�Kilroy Realty� (NYSE: KRC  ) �announced yesterday�its second-quarter dividend of $0.35 per share, the same rate it's paid since 2009.

• [By Ken McGaha]

  The four REITS I reviewed are Kilroy Realty Corp. (KRC), Kimco Realty Corp. (KIM), Eastgroup Properties (EGP) and Federal Realty Investment Trust (FRT).

10 Best Prefered Stocks To Watch Right Now: Bio-Rad Laboratories Inc. (BIO)

Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry, and other markets worldwide with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, sells, and services reagents, apparatus, and instruments used for biological research. This segment sells its products to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories, and government and industrial research facilities. The Clinical Diagnostics segment develops, manufactures, sells, and services automated test systems, informatics systems, test kits, and specialized quality controls for the healthcare market. This segment sells its products to reference laboratories, hospital laboratories, screening faci lities, physicians? office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company was founded in 1952 and is headquartered in Hercules, California.

Advisors' Opinion:

• [By Victor Selva]

  Bio-Rad Laboratories Inc. (BIO) is a manufacturer and distributor of its own life science research and clinical diagnostics products. The company has two primary segments: Life Science and Clinical Diagnostics. The company sells its products and services to a diverse client base comprised of scientific research, healthcare, education and government customers.

• [By Seth Jayson]

  Bio-Rad Laboratories (NYSE: BIO  ) reported earnings on May 7. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Bio-Rad Laboratories met expectations on revenues and whiffed on earnings per share.

10 Best Prefered Stocks To Watch Right Now: Whiting USA Trust I(WHX)

Whiting USA Trust I is a REIT. The trust was founded in 2007 and is based in Austin, Texas.

Advisors' Opinion:

• [By Roberto Pedone]

  Another name that's starting to move within range of triggering a big breakout trade is Whiting USA Trust I (WHX). This stock hasn't done much so far in 2013, with shares up just 4.5%.

  If you look at the chart for Whiting USA Trust I, you'll notice that this stock has been uptrending strong for the last few weeks, with shares moving higher from its low of $3.65 to its intraday high of $4.87 a share. During that move, shares of WHX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now spiked shares of WHX back above both its 50-day and 200-day moving averages, which is bullish. Shares of WHX are now quickly moving within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in WHX if it manages to break out above some near-term overhead resistance levels at $4.90 to $5.04 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 321,220 shares. If that breakout triggers soon, then WHX will set up to re-test or possibly take out its next major overhead resistance levels at $6.23 to $8.01 a share.

  Traders can look to buy WHX off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $4.12 a share. One can also buy WHX off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

10 Best Prefered Stocks To Watch Right Now: Abbott Laboratories(ABT)

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease; dyslipidemia; HIV infection; prostate cancer, endometriosis and central precocious puberty, and anemia caused by uterine fibroids; respiratory syncytial virus; adult males who have low or no testosterone; secondary hyperparathyroidism; hypothyroidism; and pancreatic exocrine insufficiency, as well as anesthesia products. It also provides diagnostic products, such as immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-b ased tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. In addition, the company offers a line of pediatric and adult nutritional products. Further, it provides coronary, endovascular, vessel closure, and structural heart devices, such as drug-eluting stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, carotid stent systems, percutaneous valve repair systems, and drug eluting bioresorbable vascular products. Additionally, the company provides blood glucose monitoring meters, test strips, data management software, and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, lasik surgery, contact lens, and dry eye products, as well as branded generic pharmaceutical products. Abbott primarily serves retailers, wholesalers, hospitals, and health care facilities. Abbott was founded in 1888 and is headquartered in Abbott Park, Illinois.

Advisors' Opinion:

• [By Philip Springer]

  This was a big week for the global pharmaceutical industry. First, rumors of one deal suggested a possible return to the industry’s old self-destructive ways. But then two other transactions were announced that signaled continuation of a newer trend that’s much healthier for shareholders.
  
  On Monday, it was reported that New York-based Pfizer Inc. (NYSE: PFE) had been in talks to acquire AstraZeneca PLC (NYSE: AZN), headquartered in London, for over $100 billion. The companies apparently broke off the discussions.
  
  If such a transaction were to occur, it would be the latest in a long series of megamergers that characterized the corporate strategies of Pfizer, Swiss drug giant Novartis AG (NYSE: NVS) and others in the 1990s and 2000s. Back then, the aim was to acquire rivals in multibillion-dollar deals that broadened the buyers’ businesses to cover more diseases and new health-care areas.
  
  The catalyst for this buying binge was the so-called patent cliff, in which some of the sector’s biggest drugs faced the loss of patents that protected them from competition, resulting in reduced revenues and earnings.
  
  Since then, however, the patent cliff problem has waned because many of those patent expirations have already occurred. And the bigger, combined companies generally have come up short on development of new blockbuster drugs. Also, excessive diversification has brought weak competitive positions in some niches.
  
  But the current industry trend is for companies to focus more on their core strengths instead of diversifying. Pfizer, Bristol-Myers Squibb (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) have made such moves over the last few years in order to focus on what they consider higher-growth prospects.
  
  Tuesday brought more of the same. Novartis and UK-based GlaxoSmithKline (NYSE: GSK) announced more than $20 billion in deals. Novartis is to sell its animal-drugs busi

• [By Ben Rooney]

  The ruble and Moscow stock index were stronger, continuing their recovery from sharp losses earlier this year as fears about an escalation of the crisis in Ukraine fade. A ceasefire between government forces and pro-Russian separatists declared last Friday appears to be holding. Sentiment was also improving after Abbott Laboratories (ABT) said Monday it would buy Russian pharmaceutical company Veropharm for as much as $495 million, underlining the waning threat of sanctions.

• [By Maxx Chatsko]

  After spinning off its pharmaceutical business -- and most of its dividend, essentially -- you may think Abbott Laboratories (NYSE: ABT  ) is relegated to a boring medical-device company. Heart stents just aren't as sexy as the megablockbuster drugs now being wielded by AbbVie� (NYSE: ABBV  ) . The spinoff also took a promising�pipeline and most of the former company's dividend, which may make investors think twice about owning a slow-growing, mediocre-paying company such as Abbott.�

• [By Monica Gerson]

  Abbott Laboratories (NYSE: ABT) is expected to report its Q3 earnings at $0.51 per share on revenue of $5.40 billion.

  Pepsico (NYSE: PEP) is estimated to report its Q3 earnings at $1.17 per share on revenue of $16.96 billion.

10 Best Prefered Stocks To Watch Right Now: Pound/Rand(PX)

Praxair, Inc. engages in the production, distribution, and sale atmospheric and process gases, as well as surface coatings in North America, Europe, South America, and Asia. The company offers atmospheric gases, such as oxygen, nitrogen, argon, and rare gases; and process gases comprising carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene. It also designs, engineers, and builds equipment that produces industrial gases; and manufactures precious metal and ceramic sputtering targets used primarily in the production of semiconductors. In addition, the company supplies surface coatings consisting of wear-resistant and high-temperature corrosion-resistant metallic and ceramic coatings and powders to the aircraft, energy, printing, textile, plastics, primary metals, petrochemical, and other industries. Further, it provides electric arc, plasma, and oxygen fuel spray equipment, as well as arc and flame wire equipment used for the application of wea r-resistant coatings; and distributes welding equipment purchased from independent manufacturers. The company sells its products primarily through independent distributors. It serves various industries, such as healthcare, petroleum refining, computer-chip manufacturing, beverage carbonation, fiber-optics, steel making, aerospace, chemicals, and water treatment industries. The company was founded in 1907 and is headquartered in Danbury, Connecticut.

Advisors' Opinion:

• [By Rich Duprey]

  Industrial gas maker Praxair (NYSE: PX  ) announced today it is expanding its presence in southern Russia with the acquisition of Volgograd Oxygen Factory, an�industrial gas producer with�some 2,000 customers across the�steel, aerospace, health care, and food and beverage industries, which it says will offer "immediate synergies" with Praxair's newly built�air separation plant in�Volgograd.

• [By Ben Levisohn]

  As a reminder, Air Products & Chemicals was in the low $90s when activist Bill Ackman told investors in July 2013 that he had taken a major position in a large-cap, investment-grade US corporation. Since then Air Products & Chemicals has closed its valuation gap with Praxair (PX), although restructuring has been limited so far.

• [By Marc Bastow]

  Industrial gasses supplier Praxair (PX) raised its quarterly dividend 8% to 65 cents per share, payable on Mar. 17 to shareholders of record as of Mar. 7.
  PX Dividend Yield: 2.08%

• [By Tom Rojas and Maria Armental var popups = dojo.query(".socialByline .popC"); ]

  Praxair Inc.'s(PX) second-quarter earnings grew nearly 5% as new projects in North America and Asia helped drive overall sales growth, but the company sounded a cautious tone for the remainder of the year. Shares were inactive premarket.

10 Best Prefered Stocks To Watch Right Now: AKB Mosoblbank OAO (MOBB)

AKB MOSOBLBANK OAO (AKB MOSOBLBANK OJSC) is a Russia-based commercial bank. The Company focuses on the provision of various types of banking services to both individual and corporate clients. The Bank offers its services through the network of 400 offices and automated teller machines (ATM), located across the Russian Federation. In addition, it has 23 branches in such cities as: Rostov na Donu, Samara, Astrakhan, Arkhangelsk, Nizhny Novgorod, Omsk, Tyumen, Yakutsk, Grozny, Kemerovo and Vladivostok, among others. As of May 25, 2012, the Company�� major shareholder was Respublikanskaya Finansovaya Korporatsiya OAO with a stake of 74.19%. Advisors' Opinion:

• [By Corinne Gretler]

  UBS, Switzerland�� largest bank, rallied to a two-year high. Philips, the Dutch maker of light bulbs and electric toothbrushes, gained for an eighth day. Portugal�� PSI-20 Index (PSI20) advanced 2.3 percent as President Anibal Cavaco Silva affirmed that he doesn�� want to call early elections. Mobistar (MOBB) SA slumped the most on record after the Belgian mobile-phone company cut profit forecasts and suspended its dividend.